Coronavirus information

Visitor restrictions, information for patients and more.

View coronavirus information

FOI 0530 2019/20 Treatment of Breast Cancer and Urothelial Cancer Patients

Freedom of Information Request 0530 2019/20

I have a Freedom of Information request that I wonder if you could help me with in relation to the treatment of Breast Cancer and Urothelial Cancer Patients

1. Within your health trust how many patients are currently [within the past 3 months] being treated with the following for breast cancer ?

Abemaciclib + aromatase inhibitor *

Abemaciclib + Fulvestrant

Alpelisib + Fulvestrant

Atezolizumab

Bevacizumab

Eribulin

Everolimus + Exemestane

Fulvestrant as a single agent

Gemcitabine + paclitaxel

Lapatinib

Neratinib

Olaparib

Palbociclib + aromatase inhibitor*

Pertuzumab + trastuzumab + docetaxel

Ribociclib + aromatase inhibitor*

Ribociclib + Fulvestrant

Talazoparib

Herceptin SC

Herceptin IV

Transtuzumab biosimilar SC

Transtuzumab biosimilar IV

Trastuzumab emtansine

Other active systemic anti-cancer therapy **

*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole
**eg. docetaxel, vinorelbine or capecitabine as a single agent

2. How many patients are being treated for

2a Neo-adjuvant breast cancer;

Transtuzumab total SC

Transtuzumab total IV

2.b Adjuvant breast cancer;

Transtuzumab total SC

Transtuzumab total IV

3. In the past 3 months, how many Urothelial cancer patients were treated with;

Atezolizumab

Carboplatinum in combination with another agent

Carboplatinum single agent

Cisplatinum in combination with another agent

Cisplatinum single agent

Nivolumab

Pembrolizumab

Any other chemo regimen without cisplatinum or carboplatinum

Other active systemic anti-cancer therapy [please state]

Palliative care only

FOI 0530

Thinking of going to Accident and Emergency but not sure if you need to? Try our handy symptom checker.

Try ask A&E

We're improving the accessibility of our websites. If you can't access any content or if you would like to request information in another format, please view our accessibility statement.